Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Otolaryngology | 18 | 2021 | 676 | 5.770 |
Why?
|
Neuroma, Acoustic | 29 | 2024 | 453 | 5.590 |
Why?
|
Publishing | 9 | 2020 | 834 | 3.500 |
Why?
|
Neurofibromatosis 2 | 18 | 2024 | 385 | 3.000 |
Why?
|
Review Literature as Topic | 3 | 2021 | 333 | 1.960 |
Why?
|
Neurilemmoma | 10 | 2024 | 524 | 1.900 |
Why?
|
Periodicals as Topic | 10 | 2020 | 1446 | 1.850 |
Why?
|
Meta-Analysis as Topic | 4 | 2021 | 1364 | 1.740 |
Why?
|
Hearing Loss | 9 | 2023 | 768 | 1.620 |
Why?
|
Neurofibromatoses | 3 | 2024 | 299 | 1.380 |
Why?
|
Temporal Bone | 7 | 2024 | 683 | 1.310 |
Why?
|
Otologic Surgical Procedures | 5 | 2020 | 147 | 1.210 |
Why?
|
Congresses as Topic | 3 | 2020 | 795 | 1.130 |
Why?
|
Neurofibromin 2 | 10 | 2021 | 270 | 1.100 |
Why?
|
Cochlear Implants | 6 | 2019 | 335 | 1.060 |
Why?
|
Deafness | 6 | 2023 | 455 | 1.030 |
Why?
|
Tinnitus | 3 | 2024 | 193 | 1.020 |
Why?
|
International Cooperation | 4 | 2020 | 1421 | 0.780 |
Why?
|
X-Ray Microtomography | 1 | 2024 | 432 | 0.780 |
Why?
|
Phenylbutyrates | 4 | 2021 | 72 | 0.770 |
Why?
|
Sinus Thrombosis, Intracranial | 1 | 2021 | 110 | 0.710 |
Why?
|
Ear, Inner | 2 | 2024 | 422 | 0.700 |
Why?
|
Ear Neoplasms | 3 | 2012 | 118 | 0.630 |
Why?
|
Skin Neoplasms | 4 | 2024 | 5722 | 0.550 |
Why?
|
Histone Deacetylase Inhibitors | 4 | 2021 | 774 | 0.540 |
Why?
|
Editorial Policies | 2 | 2020 | 457 | 0.520 |
Why?
|
Ganglia | 2 | 2015 | 87 | 0.520 |
Why?
|
Aerosols | 5 | 2021 | 632 | 0.520 |
Why?
|
Endolymph | 1 | 2015 | 20 | 0.510 |
Why?
|
Cochlear Implantation | 5 | 2016 | 314 | 0.490 |
Why?
|
Hearing Loss, Conductive | 3 | 2020 | 159 | 0.480 |
Why?
|
Dissection | 3 | 2012 | 299 | 0.480 |
Why?
|
Hearing | 5 | 2023 | 497 | 0.470 |
Why?
|
Speech Perception | 5 | 2020 | 508 | 0.460 |
Why?
|
Facial Nerve | 2 | 2007 | 277 | 0.460 |
Why?
|
Cranial Fossa, Middle | 1 | 2013 | 29 | 0.460 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 2 | 2020 | 320 | 0.460 |
Why?
|
Semicircular Canals | 1 | 2015 | 200 | 0.440 |
Why?
|
Meningioma | 8 | 2021 | 1209 | 0.440 |
Why?
|
Hearing Aids | 2 | 2020 | 58 | 0.440 |
Why?
|
Stapes Surgery | 2 | 2022 | 60 | 0.430 |
Why?
|
Rhytidoplasty | 1 | 2013 | 63 | 0.430 |
Why?
|
Hearing Loss, Sensorineural | 4 | 2021 | 781 | 0.420 |
Why?
|
Cochlea | 3 | 2022 | 840 | 0.420 |
Why?
|
Surgical Wound Dehiscence | 1 | 2013 | 216 | 0.410 |
Why?
|
Hearing Tests | 1 | 2012 | 123 | 0.400 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1278 | 0.400 |
Why?
|
Otosclerosis | 2 | 2022 | 113 | 0.400 |
Why?
|
Cadaver | 7 | 2024 | 1342 | 0.390 |
Why?
|
Craniotomy | 2 | 2013 | 740 | 0.380 |
Why?
|
Societies, Medical | 2 | 2020 | 3834 | 0.340 |
Why?
|
Humans | 91 | 2024 | 752810 | 0.320 |
Why?
|
Meningeal Neoplasms | 7 | 2021 | 1232 | 0.310 |
Why?
|
Pulmonary Embolism | 1 | 2021 | 2515 | 0.300 |
Why?
|
Chondroblastoma | 1 | 2007 | 48 | 0.300 |
Why?
|
Vestibulocochlear Nerve | 1 | 2007 | 115 | 0.300 |
Why?
|
Vestibulocochlear Nerve Diseases | 1 | 2007 | 33 | 0.290 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 248 | 0.290 |
Why?
|
Mastoid | 3 | 2020 | 95 | 0.290 |
Why?
|
Cerebellopontine Angle | 1 | 2007 | 52 | 0.290 |
Why?
|
Cerebrospinal Fluid Rhinorrhea | 1 | 2007 | 87 | 0.290 |
Why?
|
User-Computer Interface | 2 | 2012 | 1405 | 0.280 |
Why?
|
Plasmacytoma | 1 | 2007 | 172 | 0.280 |
Why?
|
Eukaryotic Initiation Factor-4A | 2 | 2017 | 25 | 0.280 |
Why?
|
Labyrinth Diseases | 1 | 2008 | 151 | 0.280 |
Why?
|
Eustachian Tube | 1 | 2007 | 95 | 0.280 |
Why?
|
Skull Neoplasms | 1 | 2007 | 173 | 0.270 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2007 | 134 | 0.270 |
Why?
|
Eukaryotic Initiation Factor-4G | 2 | 2017 | 69 | 0.270 |
Why?
|
Peer Review, Research | 3 | 2018 | 340 | 0.270 |
Why?
|
Eukaryotic Initiation Factor-4E | 2 | 2017 | 112 | 0.260 |
Why?
|
Facial Paralysis | 2 | 2020 | 345 | 0.260 |
Why?
|
Spinal Cord Neoplasms | 1 | 2008 | 265 | 0.260 |
Why?
|
Triterpenes | 2 | 2017 | 81 | 0.250 |
Why?
|
Angiofibroma | 1 | 2005 | 55 | 0.250 |
Why?
|
Ependymoma | 1 | 2008 | 320 | 0.240 |
Why?
|
Ear Canal | 1 | 2005 | 146 | 0.240 |
Why?
|
Synchrotrons | 1 | 2024 | 38 | 0.230 |
Why?
|
Auditory Threshold | 3 | 2020 | 370 | 0.230 |
Why?
|
Genes, Neurofibromatosis 2 | 3 | 2012 | 123 | 0.220 |
Why?
|
Speech Intelligibility | 2 | 2021 | 79 | 0.220 |
Why?
|
Labyrinthine Fluids | 1 | 2022 | 15 | 0.220 |
Why?
|
Phonetics | 2 | 2014 | 207 | 0.210 |
Why?
|
Foreign Bodies | 1 | 2006 | 392 | 0.210 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3066 | 0.210 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3185 | 0.210 |
Why?
|
Cerebellar Neoplasms | 1 | 2007 | 587 | 0.200 |
Why?
|
Reflex, Vestibulo-Ocular | 1 | 2022 | 86 | 0.190 |
Why?
|
Transcription Initiation Site | 1 | 2002 | 187 | 0.190 |
Why?
|
Magnetic Resonance Imaging | 12 | 2024 | 36038 | 0.190 |
Why?
|
Hearing Loss, Sudden | 1 | 2021 | 45 | 0.190 |
Why?
|
Organophosphorus Compounds | 1 | 2021 | 205 | 0.180 |
Why?
|
DNA, Complementary | 2 | 2006 | 1988 | 0.180 |
Why?
|
Computer Simulation | 2 | 2012 | 6176 | 0.180 |
Why?
|
Mice, SCID | 6 | 2015 | 2617 | 0.170 |
Why?
|
Middle Ear Ventilation | 1 | 2020 | 97 | 0.170 |
Why?
|
Nose Diseases | 1 | 2020 | 79 | 0.170 |
Why?
|
Ethics Committees, Research | 1 | 2021 | 195 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2021 | 3552 | 0.170 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2008 | 3788 | 0.170 |
Why?
|
Dizziness | 1 | 2022 | 244 | 0.160 |
Why?
|
Peer Review | 1 | 2021 | 218 | 0.160 |
Why?
|
Quality of Life | 3 | 2024 | 13162 | 0.160 |
Why?
|
Capsid | 1 | 2021 | 426 | 0.160 |
Why?
|
Cues | 2 | 2014 | 865 | 0.160 |
Why?
|
Pyridazines | 2 | 2018 | 200 | 0.160 |
Why?
|
Imaging, Three-Dimensional | 1 | 2012 | 4035 | 0.160 |
Why?
|
Retrospective Studies | 14 | 2023 | 79160 | 0.160 |
Why?
|
Ear Diseases | 1 | 2020 | 175 | 0.160 |
Why?
|
Organizational Policy | 1 | 2021 | 426 | 0.160 |
Why?
|
Schwann Cells | 2 | 2017 | 197 | 0.150 |
Why?
|
Otitis Media | 1 | 2020 | 285 | 0.150 |
Why?
|
Alternative Splicing | 2 | 2006 | 1093 | 0.150 |
Why?
|
Postural Balance | 1 | 2022 | 610 | 0.140 |
Why?
|
Mifepristone | 1 | 2018 | 150 | 0.140 |
Why?
|
Point Mutation | 1 | 2002 | 1591 | 0.140 |
Why?
|
Brassica | 1 | 2016 | 39 | 0.140 |
Why?
|
Isothiocyanates | 1 | 2016 | 48 | 0.140 |
Why?
|
Peptide Chain Initiation, Translational | 1 | 2017 | 99 | 0.140 |
Why?
|
Antineoplastic Agents | 7 | 2017 | 13558 | 0.140 |
Why?
|
Nose | 1 | 2020 | 511 | 0.140 |
Why?
|
Dependovirus | 1 | 2021 | 698 | 0.140 |
Why?
|
Middle Aged | 19 | 2024 | 217250 | 0.130 |
Why?
|
Drug Evaluation, Preclinical | 3 | 2018 | 1347 | 0.130 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5598 | 0.130 |
Why?
|
Eukaryotic Initiation Factor-4F | 1 | 2016 | 42 | 0.130 |
Why?
|
Drug Repositioning | 1 | 2018 | 233 | 0.130 |
Why?
|
Evoked Potentials, Auditory | 2 | 2016 | 529 | 0.130 |
Why?
|
Patient Care | 1 | 2021 | 624 | 0.130 |
Why?
|
Patient Selection | 2 | 2019 | 4239 | 0.130 |
Why?
|
Intracranial Hemorrhages | 1 | 2021 | 843 | 0.130 |
Why?
|
Bone Neoplasms | 1 | 2007 | 2513 | 0.130 |
Why?
|
Postoperative Complications | 3 | 2007 | 15438 | 0.130 |
Why?
|
Aged | 14 | 2024 | 166705 | 0.120 |
Why?
|
Access to Information | 1 | 2018 | 318 | 0.120 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 557 | 0.120 |
Why?
|
Female | 26 | 2024 | 386339 | 0.120 |
Why?
|
Male | 26 | 2024 | 355160 | 0.120 |
Why?
|
Psychoacoustics | 1 | 2014 | 57 | 0.120 |
Why?
|
Language | 2 | 2014 | 1508 | 0.120 |
Why?
|
Aged, 80 and over | 8 | 2021 | 58347 | 0.120 |
Why?
|
p21-Activated Kinases | 1 | 2015 | 128 | 0.120 |
Why?
|
Cell Line, Tumor | 10 | 2021 | 16739 | 0.120 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2014 | 91 | 0.110 |
Why?
|
Adult | 19 | 2023 | 217168 | 0.110 |
Why?
|
Pyrimidines | 3 | 2021 | 2979 | 0.110 |
Why?
|
Endoscopy | 2 | 2020 | 1838 | 0.110 |
Why?
|
Occupational Exposure | 2 | 2020 | 1798 | 0.110 |
Why?
|
Audiometry, Pure-Tone | 2 | 2016 | 210 | 0.100 |
Why?
|
Language Development | 1 | 2013 | 183 | 0.100 |
Why?
|
Furans | 1 | 2013 | 193 | 0.100 |
Why?
|
Oncogene Proteins v-erbB | 1 | 2012 | 17 | 0.100 |
Why?
|
Cell Proliferation | 8 | 2016 | 10358 | 0.100 |
Why?
|
Embryonic Development | 2 | 2007 | 711 | 0.100 |
Why?
|
Immunohistochemistry | 7 | 2012 | 11004 | 0.100 |
Why?
|
History, 21st Century | 1 | 2018 | 1560 | 0.100 |
Why?
|
Information Dissemination | 1 | 2020 | 1132 | 0.100 |
Why?
|
Least-Squares Analysis | 1 | 2012 | 366 | 0.100 |
Why?
|
United States | 5 | 2020 | 71434 | 0.090 |
Why?
|
Meninges | 1 | 2012 | 196 | 0.090 |
Why?
|
Imidazoles | 1 | 2017 | 1173 | 0.090 |
Why?
|
Bone Conduction | 2 | 2022 | 102 | 0.090 |
Why?
|
Lasers, Gas | 1 | 2012 | 92 | 0.090 |
Why?
|
Central Nervous System Depressants | 1 | 2011 | 162 | 0.090 |
Why?
|
Cyclin D1 | 2 | 2017 | 453 | 0.090 |
Why?
|
Tumor Burden | 2 | 2015 | 1875 | 0.090 |
Why?
|
Cyclins | 2 | 2017 | 594 | 0.090 |
Why?
|
History, 20th Century | 1 | 2018 | 2761 | 0.090 |
Why?
|
Mutation | 4 | 2009 | 29712 | 0.090 |
Why?
|
Multiple Myeloma | 1 | 2007 | 5118 | 0.080 |
Why?
|
Mice | 13 | 2021 | 80551 | 0.080 |
Why?
|
Disease Progression | 2 | 2019 | 13403 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2007 | 9207 | 0.080 |
Why?
|
Health Planning Guidelines | 1 | 2009 | 150 | 0.080 |
Why?
|
Animals | 18 | 2021 | 166825 | 0.080 |
Why?
|
DNA Mutational Analysis | 3 | 2009 | 4112 | 0.080 |
Why?
|
Melanoma | 1 | 2007 | 5620 | 0.080 |
Why?
|
Microsurgery | 1 | 2014 | 778 | 0.080 |
Why?
|
Pandemics | 4 | 2020 | 8499 | 0.080 |
Why?
|
Treatment Outcome | 8 | 2023 | 64288 | 0.080 |
Why?
|
Osteosclerosis | 1 | 2008 | 40 | 0.080 |
Why?
|
Single-Blind Method | 1 | 2012 | 1574 | 0.080 |
Why?
|
Stapes | 1 | 2008 | 89 | 0.080 |
Why?
|
Antiviral Agents | 1 | 2020 | 3033 | 0.080 |
Why?
|
Vestibular Nerve | 2 | 2012 | 101 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2023 | 39089 | 0.080 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 2011 | 0.070 |
Why?
|
Protons | 2 | 2023 | 1121 | 0.070 |
Why?
|
Bell Palsy | 1 | 2007 | 39 | 0.070 |
Why?
|
Clinical Trials as Topic | 3 | 2012 | 7997 | 0.070 |
Why?
|
Tympanic Membrane Perforation | 1 | 2006 | 44 | 0.070 |
Why?
|
Young Adult | 6 | 2021 | 57732 | 0.070 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2009 | 626 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2012 | 1389 | 0.070 |
Why?
|
Bandages | 1 | 2007 | 267 | 0.070 |
Why?
|
Melatonin | 1 | 2011 | 667 | 0.060 |
Why?
|
Anticoagulants | 1 | 2021 | 4830 | 0.060 |
Why?
|
Differential Threshold | 1 | 2005 | 80 | 0.060 |
Why?
|
Program Development | 1 | 2012 | 1287 | 0.060 |
Why?
|
Adolescent | 7 | 2021 | 86822 | 0.060 |
Why?
|
Cochlear Nerve | 1 | 2007 | 202 | 0.060 |
Why?
|
Clinical Competence | 2 | 2012 | 4713 | 0.060 |
Why?
|
Genetic Testing | 3 | 2007 | 3504 | 0.060 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2006 | 342 | 0.060 |
Why?
|
Tympanic Membrane | 1 | 2006 | 227 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3600 | 0.060 |
Why?
|
Laser Therapy | 1 | 2012 | 1092 | 0.060 |
Why?
|
Promoter Regions, Genetic | 3 | 2006 | 5780 | 0.060 |
Why?
|
Sulfonamides | 2 | 2018 | 1963 | 0.060 |
Why?
|
Ear, Middle | 1 | 2006 | 336 | 0.060 |
Why?
|
Bone Remodeling | 1 | 2008 | 579 | 0.060 |
Why?
|
Teaching | 1 | 2012 | 1159 | 0.060 |
Why?
|
Memory | 1 | 2014 | 2176 | 0.060 |
Why?
|
Operating Rooms | 2 | 2020 | 784 | 0.060 |
Why?
|
Interleukin-16 | 1 | 2023 | 34 | 0.060 |
Why?
|
Ossicular Prosthesis | 1 | 2003 | 36 | 0.060 |
Why?
|
Equipment Design | 1 | 2012 | 3512 | 0.060 |
Why?
|
Child | 6 | 2021 | 78996 | 0.060 |
Why?
|
Consensus | 2 | 2011 | 3037 | 0.060 |
Why?
|
Program Evaluation | 1 | 2012 | 2464 | 0.050 |
Why?
|
Cell Survival | 3 | 2018 | 5775 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2005 | 955 | 0.050 |
Why?
|
Tumor Cells, Cultured | 3 | 2017 | 6137 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1830 | 0.050 |
Why?
|
GC Rich Sequence | 1 | 2002 | 19 | 0.050 |
Why?
|
Electroencephalography | 2 | 2016 | 6151 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7294 | 0.050 |
Why?
|
Research Design | 3 | 2012 | 6118 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2009 | 9460 | 0.050 |
Why?
|
Sp1 Transcription Factor | 1 | 2002 | 141 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2018 | 8420 | 0.050 |
Why?
|
Polyadenylation | 1 | 2002 | 116 | 0.050 |
Why?
|
Prognosis | 3 | 2007 | 29369 | 0.050 |
Why?
|
Apoptosis | 5 | 2016 | 9436 | 0.050 |
Why?
|
Sneezing | 1 | 2020 | 17 | 0.050 |
Why?
|
Postoperative Period | 1 | 2005 | 1806 | 0.040 |
Why?
|
Decompression, Surgical | 1 | 2005 | 595 | 0.040 |
Why?
|
Electromyography | 1 | 2005 | 1379 | 0.040 |
Why?
|
Fluorescein | 1 | 2020 | 173 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2017 | 2440 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2005 | 1633 | 0.040 |
Why?
|
Electric Stimulation | 1 | 2005 | 1734 | 0.040 |
Why?
|
Cell Cycle | 3 | 2013 | 2926 | 0.040 |
Why?
|
Logistic Models | 2 | 2005 | 13277 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2008 | 9355 | 0.040 |
Why?
|
Otitis Media with Effusion | 1 | 2020 | 114 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2021 | 904 | 0.040 |
Why?
|
RNA, Messenger | 3 | 2006 | 12737 | 0.040 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2002 | 656 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 12154 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3330 | 0.040 |
Why?
|
Contrast Media | 1 | 2012 | 5276 | 0.040 |
Why?
|
Pyrazoles | 1 | 2009 | 1988 | 0.040 |
Why?
|
Transduction, Genetic | 1 | 2021 | 895 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 874 | 0.040 |
Why?
|
Down-Regulation | 2 | 2002 | 2910 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2006 | 2368 | 0.040 |
Why?
|
Protein-Tyrosine Kinases | 2 | 2021 | 2411 | 0.040 |
Why?
|
Transgenes | 1 | 2021 | 999 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2002 | 1056 | 0.040 |
Why?
|
Paxillin | 1 | 2017 | 86 | 0.040 |
Why?
|
RNA, Small Interfering | 2 | 2017 | 3447 | 0.040 |
Why?
|
Algorithms | 3 | 2018 | 13905 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2007 | 2714 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2011 | 14296 | 0.040 |
Why?
|
Sulfoxides | 1 | 2016 | 46 | 0.040 |
Why?
|
G2 Phase | 1 | 2017 | 133 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2002 | 1693 | 0.040 |
Why?
|
Receptors, Platelet-Derived Growth Factor | 1 | 2017 | 178 | 0.040 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2017 | 185 | 0.030 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2017 | 283 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2017 | 319 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2021 | 1204 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 2002 | 6058 | 0.030 |
Why?
|
Particle Size | 1 | 2020 | 1633 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2011 | 18918 | 0.030 |
Why?
|
Exons | 1 | 2002 | 2383 | 0.030 |
Why?
|
Phosphorylation | 3 | 2012 | 8314 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 25540 | 0.030 |
Why?
|
Microscopy | 1 | 2020 | 882 | 0.030 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2006 | 3589 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2007 | 12918 | 0.030 |
Why?
|
Morpholines | 1 | 2018 | 583 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2017 | 717 | 0.030 |
Why?
|
Phytotherapy | 1 | 2016 | 292 | 0.030 |
Why?
|
src-Family Kinases | 1 | 2017 | 534 | 0.030 |
Why?
|
Speech Discrimination Tests | 1 | 2014 | 35 | 0.030 |
Why?
|
Systems Biology | 1 | 2018 | 483 | 0.030 |
Why?
|
Immunoenzyme Techniques | 2 | 2011 | 1708 | 0.030 |
Why?
|
Sesterterpenes | 1 | 2013 | 6 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2011 | 17960 | 0.030 |
Why?
|
Occupational Health | 1 | 2020 | 796 | 0.030 |
Why?
|
Blotting, Western | 2 | 2012 | 5035 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2002 | 1988 | 0.030 |
Why?
|
Multilingualism | 1 | 2014 | 87 | 0.030 |
Why?
|
Speech Acoustics | 1 | 2014 | 154 | 0.030 |
Why?
|
Doxycycline | 1 | 2015 | 328 | 0.030 |
Why?
|
Reoperation | 1 | 2003 | 4257 | 0.030 |
Why?
|
Spinal Cord | 1 | 2021 | 1804 | 0.030 |
Why?
|
Infection Control | 1 | 2020 | 971 | 0.030 |
Why?
|
Binding Sites | 1 | 2002 | 6031 | 0.030 |
Why?
|
Quinolines | 1 | 2018 | 748 | 0.030 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 870 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2017 | 1615 | 0.030 |
Why?
|
Hep G2 Cells | 1 | 2013 | 387 | 0.030 |
Why?
|
Genetic Vectors | 1 | 2021 | 3354 | 0.020 |
Why?
|
Neoplasms | 1 | 2021 | 21810 | 0.020 |
Why?
|
Risk Assessment | 2 | 2020 | 23785 | 0.020 |
Why?
|
Immunoblotting | 1 | 2015 | 1649 | 0.020 |
Why?
|
Internship and Residency | 1 | 2012 | 5810 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1868 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 53833 | 0.020 |
Why?
|
Base Sequence | 1 | 2002 | 12432 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3582 | 0.020 |
Why?
|
Signal Transduction | 5 | 2017 | 23235 | 0.020 |
Why?
|
MAP Kinase Signaling System | 1 | 2017 | 1480 | 0.020 |
Why?
|
Pyridones | 1 | 2015 | 766 | 0.020 |
Why?
|
Auditory Brain Stem Implants | 1 | 2009 | 31 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2011 | 403 | 0.020 |
Why?
|
Gene Expression | 1 | 2002 | 7581 | 0.020 |
Why?
|
Acoustic Stimulation | 1 | 2014 | 1239 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2007 | 15695 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 39885 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17608 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 592 | 0.020 |
Why?
|
Patient Simulation | 1 | 2010 | 296 | 0.020 |
Why?
|
Standard of Care | 1 | 2011 | 548 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2016 | 6112 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4573 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2009 | 17650 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2011 | 2475 | 0.020 |
Why?
|
Child, Preschool | 2 | 2013 | 41656 | 0.020 |
Why?
|
Ectoderm | 1 | 2006 | 137 | 0.020 |
Why?
|
Cyclin D3 | 1 | 2006 | 54 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2843 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10475 | 0.020 |
Why?
|
beta-Galactosidase | 1 | 2006 | 572 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 2037 | 0.020 |
Why?
|
Quinazolines | 1 | 2012 | 1351 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2023 | 21857 | 0.020 |
Why?
|
Risk Factors | 2 | 2020 | 73418 | 0.020 |
Why?
|
Cohort Studies | 1 | 2007 | 40996 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2006 | 279 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 20350 | 0.010 |
Why?
|
Neural Crest | 1 | 2006 | 278 | 0.010 |
Why?
|
Benchmarking | 1 | 2010 | 1036 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2002 | 11882 | 0.010 |
Why?
|
Nervous System | 1 | 2006 | 540 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7407 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2006 | 1896 | 0.010 |
Why?
|
Radiosurgery | 1 | 2011 | 1335 | 0.010 |
Why?
|
Computer-Assisted Instruction | 1 | 2002 | 361 | 0.010 |
Why?
|
Retinoblastoma Protein | 1 | 2002 | 667 | 0.010 |
Why?
|
Pilot Projects | 1 | 2012 | 8449 | 0.010 |
Why?
|
Brain Mapping | 1 | 2014 | 6594 | 0.010 |
Why?
|
RNA | 1 | 2008 | 2701 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3725 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14323 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12322 | 0.010 |
Why?
|
Survival Rate | 1 | 2011 | 12751 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 10798 | 0.010 |
Why?
|
Sleep | 1 | 2011 | 4712 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2012 | 9107 | 0.010 |
Why?
|
Cell Movement | 1 | 2006 | 5174 | 0.010 |
Why?
|
Carcinoma | 1 | 2006 | 2341 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19907 | 0.010 |
Why?
|
Infant | 1 | 2013 | 35673 | 0.010 |
Why?
|
Brain | 1 | 2015 | 26820 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 2002 | 14601 | 0.000 |
Why?
|
Pregnancy | 1 | 2006 | 29427 | 0.000 |
Why?
|
Prostatic Neoplasms | 1 | 2006 | 11262 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2006 | 20844 | 0.000 |
Why?
|